Y-mAbs' naxitamab shows promise in treating high-risk neuroblastoma. Explore its phase 2 success, strong cash runway, and ...

Colorado was long considered a haven for gender-affirming care. But under this Trump administration, hospitals in the state ...

Eyeing a future of improved patient outcomes, the Medical College of Wisconsin is working to advance the prevention, ...

The Institute of Cancer Research, London (ICR) welcomed the move, which follows decades of research by ICR scientists ...

In a new study, people who drank 8 or more drinks per week had over double the risk of brain lesions compared to people who ...

Revenue-generating with an exciting, diversified, largely externally funded, advanced development pipeline and multiple upcoming catalysts. Recent highlights: Global ...

Rucaparib has received regulatory approval from the European Medicines Agency (EMA) and the United States Food and Drug ...

Prostate cancer is the second leading cause of cancer death among men and more than 100 thousand cases are reported per year ...

MIAMI, FLORIDA (April 9, 2025) – A clinical trial for patients with high-grade neuroendocrine tumors is now open for ...

How do we protect ourselves through early detection without falling into a cycle of unnecessary procedures we don’t fully ...